lorcaserin(856681-05-5)is an orally administered agent and a selective 5-ht2c receptor agonist for the treatment of obesity. it had been approved for marketing in us by fda on 27 june in 2012. in clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
halobetasol propionate basic information |
product name: | halobetasol propionate |
synonyms: | ulobetasol propionate;halobetasol propionate;21-chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate;halobetasol;6 alpha-fluoroclobetasol 17-propionate;21-chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate;(6α,11β,16β)-21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione;bmy-30056 |
cas: | 66852-54-8 |
mf: | c25h31clf2o5 |
mw: | 484.96 |
einecs: | |
product categories: | steroids;inhibitors |
mol file: | 66852-54-8.mol |
halobetasol propionate chemical properties |
mp | 213-215°c |
storage temp. | refrigerator |
cas database reference |
66852-54-8(cas database reference) |